https://orcid.org/0000-0001-7191-6612
Figures & data
Figure 1 Study flowchart.
Figure 2 Randomised clinical trials at each stage of disease progression for COVID-19.
Notes: This figure illustrates broad disease stages of COVID-19 disease starting from pre-exposure to SARS-CoV-2, post-exposure, early infection in the outpatient setting, hospitalization and to advanced disease manifestation that requires intensive care.
Figure 3 Distribution of number of arms for (A) all and (B) (hydroxy)chloroquine randomized clinical trials for COVID-19, arranged by clinical setting.
Notes: Each circle represents an individual trial. The colour of each circle represents the sample size: red – 0, 60; orange – 60, 140; green – 140, 400; blue – 400, 60,000 participants.
Abbreviations: PrEP, pre-exposure prophylaxis; PEP, post-exposure prophylaxis; ICU, intensive care unit.
Figure 4 Distribution of COVID-19 randomized clinical trials and enrollment target for key drugs, arranged by clinical setting.
Notes: The size of each circle represents the total sample size (recruitment) of trials. Each colour represents the patient setting: purple – PEP; red – PrEP; green – outpatient; blue – hospital or ICU.
Abbreviations: PEP, post-exposure prophylaxis; ICU, intensive care unit.
Figure 5 Treatment network for (A) pre-exposure and (B) post-exposure randomized clinical trials for COVID-19.
Notes: Each node (circle) represents an intervention and each line represents a direct comparison between different interventions.
Abbreviations: NRTIs, nucleoside reverse transcriptase inhibitors; Lopinavir/r, lopinavir/ritonavir.
Figure 6 Treatment network for (A) outpatient and (B) hospitalized or intensive care unit randomized clinical trials for COVID-19.
Notes: Each node (circle) represents an intervention and each line represents a direct comparison between different interventions.
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; Lopinavir/r, lopinavir/ritonavir; IGs, immunoglobulin.
